Detalhe da pesquisa
1.
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
; 2024 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38754055
2.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789260
3.
Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
Ann Hematol
; 100(9): 2303-2310, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34236497
4.
Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Br J Haematol
; 167(3): 327-36, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25066542
5.
Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
Eur J Haematol
; 93(6): 469-75, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24853381
6.
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.
EJHaem
; 4(4): 1081-1088, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-38024636
7.
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma.
Br J Haematol
; 159(3): 322-8, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23016878
8.
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.
Cancers (Basel)
; 14(4)2022 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205606
9.
A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.
Blood Adv
; 6(21): 5763-5773, 2022 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35973197
10.
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.
Leuk Lymphoma
; 63(5): 1058-1069, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35045765
11.
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
J Clin Oncol
; 40(11): 1196-1205, 2022 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030036
12.
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies.
Blood Adv
; 6(3): 774-784, 2022 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34844263
13.
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice.
Int J Hematol
; 116(3): 381-392, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551632
14.
Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Leukemia
; 35(3): 787-795, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32782382
15.
Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Br J Haematol
; 162(1): 130-2, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23581433
16.
Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma.
Leuk Lymphoma
; 63(7): 1746-1749, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35129412
17.
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Blood Adv
; 6(12): 3606-3610, 2022 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35271707
18.
Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury: a preliminary study.
Intensive Care Med
; 32(11): 1733-40, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17019549
19.
Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
Leukemia
; 35(3): 932, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483620
20.
Stage IV and age over 45 years are the only prognostic factors of the International Prognostic Score for the outcome of advanced Hodgkin lymphoma in the Spanish Hodgkin Lymphoma Study Group series.
Leuk Lymphoma
; 53(5): 812-9, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22185637